Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/88982
Title: Effect of hyaluronic acid/trehalose in two different formulations on signs and symptoms in patients with moderate to severe dry eye disease
Authors: Fondi, Klemens
Wozniak, Piotr A.
Schmidl, Doreen
Bata, Ahmed M.
Witkowska, Katarzyna J.
Popa-Cherecheanu, Alina
Schmetterer, Leopold
Garhöfer, Gerhard
Keywords: DRNTU::Science::Medicine
Hyaluronic Acid
Treatment Regimens
Issue Date: 2018
Source: Fondi, K., Wozniak, P. A., Schmidl, D., Bata, A. M., Witkowska, K. J., Popa-Cherecheanu, A., . . . Garhöfer, G. (2018). Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease. Journal of Ophthalmology, 2018, 4691417-. doi:10.1155/2018/4691417
Series/Report no.: Journal of Ophthalmology
Abstract: Purpose. This randomized, observer-masked, crossover study investigated the effect of two hyaluronic acid/trehalose-based containing formulations, with different physical properties, on the signs and symptoms in patients with moderate to severe dry eye disease (DED). Methods. In one group, patients received a mixture of sodium hyaluronate and trehalose (HT, Thealoz Duo®) for use during the day. In the other group, patients received a more viscous formulation consisting of hyaluronic acid, trehalose, and carbomer (HTC-gel, Thealoz Duo Gel) to use pro re nata. Both groups used HTC-gel before going to bed. Clinical standard tests for DED were performed at the beginning and end of each one-week period. Further, patient satisfaction including quality of sleep was assessed using a visual analogue scale. Results. Corneal fluorescein and conjunctival lissamine green staining scores decreased, and tear breakup time (BUT) increased for both groups (p<0.001 each). Mean instillation frequency was 3.1 ± 2.6 drops/day when using HT and 1.9 ± 2.2 drops/day when using HTC-gel (p=0.02). A significant improvement in the quality of sleep was observed with both treatments (p=0.01). Conclusions. Our results show improvement in signs and symptoms of DED in both groups. While instillation of HTC-gel resulted in a lower instillation frequency, both formulations of trehalose showed good clinical efficacy. This trial is registered with NCT02980913.
URI: https://hdl.handle.net/10356/88982
http://hdl.handle.net/10220/46031
ISSN: 2090-004X
DOI: 10.1155/2018/4691417
Rights: © 2018 Klemens Fondi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Google ScholarTM

Check

Altmetric

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.